Two cases of serious ophthalmic adverse reactions related to fibroblast growth factor receptor inhibitors
10.3760/cma.j.cn431274-20250225-00244
- VernacularTitle:成纤维细胞生长因子受体抑制剂相关的眼科严重不良反应2例
- Author:
Erqian WANG
1
;
Lei ZHANG
;
Youxin CHEN
Author Information
1. 中国医学科学院 北京协和医院眼科，北京 100730
- Publication Type:Journal Article
- Keywords:
Receptors, fibroblast growth factor;
Targeted therapy;
Drug-related side effects and adverse reactions;
Eye diseases
- From:
Journal of Chinese Physician
2025;27(5):658-661
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To report the ocular blinding adverse reactions related to fibroblast growth factor receptor (FGFR) inhibitors, in order to improve the awareness level of potential ophthalmic adverse reactions of small molecule targeted anti-tumor drugs.Methods:Two patients with intrahepatic cholangiocarcinoma admitted to Peking Union Medical College Hospital, Chinese Academy of Medical Science in 2022 were retrospectively selected. Both patients experienced ocular adverse events after targeted therapy with FGFR inhibitors.Results:One patient developed corneal epithelial lesions after taking Pemitinib orally for 4 cycles. Due to secondary pseudomonas aeruginosa infection, severe corneal ulcers and reactive endophthalmitis occurred. Despite active local and systemic treatments, irreversible vision loss was still caused. Another patient gradually experienced vision loss after taking pemitinib orally for three cycles. The vision loss sharply worsened after the 22nd month of medication. Ophthalmic examination supported the diagnosis of dilated cataract, and secondary intraocular pressure elevation occurred. After timely surgical treatment, vision and intraocular pressure returned to normal.Conclusions:While inhibitors prolong the survival period of tumor patients, they are also accompanied by potential blinding adverse reactions, which should be given clinical attention.
